12:00 AM
 | 
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MM-121: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 25 evaluable patients with refractory advanced solid tumors showed that weekly MM-121 was well tolerated with grade 1/2 nausea, diarrhea, fatigue and rash reported as the most common...

Read the full 160 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >